France Veterinary Healthcare - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The france veterinary healthcare market size was valued at USD 2.75 billion in 2025 and estimated to grow from USD 2.92 billion in 2026 to reach USD 3.92 billion by 2031, at a CAGR of 6.08% during the forecast period (2026-2031). This report is Segmented by Product (Therapeutics and Diagnostics), Animal Type (Dogs & Cats, Horses, Ruminants, and More), Route of Administration (Oral, Parenteral, and More), End User (Veterinary Hospitals & Clinics, Reference Laboratories, and More). The Market Forecasts are Provided in Terms of Value (USD).

France Veterinary Healthcare Market Trends and Insights

Technological Advancements in Veterinary Diagnostics and Therapeutics

AI tools permeate French clinics, with 69.5% of professionals using machine-learning systems for cytology and imaging. Zoetis expanded its Vetscan Imagyst platform in 2025, enabling automated lymph-node and skin-mass review, which lifts diagnostic accuracy and cuts result turnaround to minutes. Virbac’s “Day 1” mobile application allows farmers to score colostrum quality on-site, supporting neonatal immunity tracking. Large reference laboratories enhance these digital gains; Mars Petcare completed the acquisition of Cerba Vet and ANTAGENE in January 2025, adding six labs and a genetics hub to its French network. Collectively, these tools shorten treatment initiation, reduce follow-up visits, and ease the workload on an overstretched veterinarian labor force.

Rising Pet Insurance Coverage and Companion Animal Expenditure

Pet insurance penetration climbed across metropolitan France after 2024 tariff liberalization. SantéVet, Lassie, and Pety each offer plans with annual limits up to EUR 5,000 (USD 5,400), cutting out-of-pocket bills for surgeries and imaging. The share of insured dogs rose from 25% in 2024 to 32% in 2025, while cats posted a 4-percentage-point jump. Higher coverage propelled service uptake: MRI utilization grew 12% year over year, and preventive dental cleanings rose 9%. Spending aligns with a wider consumer shift toward premium veterinary nutrition, grooming, and wellness visits that keeps the France veterinary healthcare market on its growth path.

Escalating Cost of Veterinary Services and Pharmaceuticals

Base consultation fees at primary-care clinics rose from EUR 26.50 to EUR 30 (USD 32.60) in January 2025. Simultaneously, new prescription regulations moved opioids and codeine to secure pads, raising compliance overhead for practices. Consolidation contributes to tariff creep: after Mars Petcare’s expansion, U.S. lawmakers cited up-charging concerns, mirroring anecdotal price increases in French urban hospitals. Livestock producers on thin margins often postpone treatments, eroding routine disease-prevention benefits.

Other drivers and restraints analyzed in the detailed report include:

• Government-Led Livestock Disease Control Programs
• Expansion Of E-Commerce Distribution Channels for Veterinary Products
• Limited Veterinary Infrastructure in Rural Areas

Segment Analysis

Therapeutics generated 59.78% of 2025 revenue, anchoring the France veterinary healthcare market. Parasiticides and vaccines sold briskly as poultry and swine producers responded to stringent biosecurity rules, and companion-animal owners demanded broad-spectrum flea and tick solutions. Virbac’s launches, including a neonatal piglet diarrhea vaccine, highlight the pace of biologic innovation. Anti-infectives face stricter antimicrobial resistance rules, yet targeted molecules still see demand during outbreaks, sustaining double-digit product turnover.

Diagnostics, while smaller, is the fastest-growing line at 7.32% CAGR. Mars Petcare’s Cerba Vet acquisition multiplied laboratory throughput, and IDEXX bundled hematology and chemistry analyzers into subscription kits, lifting placement rates in independent clinics. AI algorithms embedded in handheld ultrasound and cytology readers reduce sample referrals and foster in-house revenues. The France veterinary healthcare market size for diagnostics is projected to top USD 1.65 billion by 2031, reflecting this adoption wave.

Dogs and cats account for 45.05% of 2025 turnover, mirroring French urban demographics that support wellness plans, orthopedic surgery, and advanced imaging. Orthopedic supplement maker Vetoquinol broadened its Flexadin range in July 2025, underlining lucrative niche expansion.

Poultry, however, records the swiftest ascent with a 6.55% CAGR. Massive duck vaccination campaigns and export-oriented breeders require continuous immunization, diagnostics, and biosafety audits. The France veterinary healthcare market share for poultry health inputs is expected to pass 15.42% by 2031 as farmers invest in resilient production systems.

Complete Report Scope:

• By Product
  • Therapeutics
    • Vaccines
    • Parasiticides
    • Anti-Infectives
    • Medical Feed Additives
    • Other Therapeutics
  • Diagnostics
    • Immunodiagnostic Tests
    • Molecular Diagnostics
    • Diagnostic Imaging
    • Clinical Chemistry
    • Other Diagnostics
• By Animal Type
  • Dogs & Cats
  • Horses
  • Ruminants
  • Swine
  • Poultry
  • Other Animal Types
• By Route Of Administration
  • Oral
  • Parenteral
  • Topical
  • Other Route of Administrations
• By End User
  • Veterinary Hospitals & Clinics
  • Reference Laboratories
  • Point-Of-Care / In-House Testing Settings
  • Academic & Research Institutes

List of Companies Covered in this Report:

• Zoetis
• Boehringer Ingelheim
• Ceva
• Virbac
• Elanco
• Merck & Co., Inc. (MSD Animal Health)
• IDEXX
• Vetoquinol
• bioMérieux
• Mars Petcare (incl. VCA/Cerba Vet)
• Covetrus
• Dechra Pharmaceuticals
• TVM Laboratoires
• IVC Evidensia
• Bimeda Holdings
• Neogen
• Henry Schein Animal Health
• Innovet
• Le Vet Pharma
• Phileo By Lesaffre

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support